Aroa Biosurgery Limited
ARX.ASXHealth Care
Market Data
$0.685
+0.0%$235.2M
69.2x
$0.010
0.00%
+0.1%
Latest Earnings
FY26 Appendix 4E and Full Year Results
26 May 2026
AROA Biosurgery delivered strong FY26 results with total revenue of NZ$103.9M (+23% YoY), exceeding guidance, driven by 54% growth in Myriad products and positive underlying momentum across the business. Normalised EBITDA surged to NZ$12.6M from NZ$4.2M in FY25, with the company maintaining a solid cash position of NZ$27.1M and no debt. FY27 guidance projects 13-23% constant currency revenue growth to NZ$115-125M, though Normalised EBITDA is expected to moderate to NZ$8-11M due to deliberate investment of ~NZ$9M in commercial expansion and product development. Key points: Revenue of NZ$103.9M exceeded FY26 guidance range of NZ$92-100M, growing 23% YoY with 54% Myriad product growth demonstrating strong operating leverage; Normalised EBITDA surged to NZ$12.6M (+200% YoY), exceeding guidance of NZ$5-8M despite cost inflation, demonstrating significant margin expansion; Strong cash generation with NZ$10.5M operating cash inflow (vs NZ$2.6M outflow in FY25), ending with NZ$27.1M cash, no debt, and net cash flow of NZ$5.1M
Recent Announcements
FY26 Full Year Results Presentation - Correction
AROA Biosurgery Limited issued a correction to its FY26 Results Investor Presentation filed on 26 May 2026, correcting a typographical error on slide 28 where "Loss before income tax (NZ GAAP)" should read "Profit (loss) before income tax (NZ GAAP)". The correction is typographical only and does not change the FY26 results, outlook, or other presentation information.
FY26 Full Year Results Presentation
Aroa Biosurgery Ltd reported FY26 full-year results exceeding guidance with total revenue of NZ$104m (+23% YoY) and normalised EBITDA of NZ$13m, achieving profitability and self-funding status with NZ$27m cash and debt-free position. Key growth was driven by Myriad product sales (+54%), Symphony RCT endpoint achievement, and direct sales channel expansion to 59% of revenue.
FY26 Appendix 4E and Full Year Results
AROA Biosurgery delivered strong FY26 results with total revenue of NZ$103.9M (+23% YoY), exceeding guidance, driven by 54% growth in Myriad products and positive underlying momentum across the business. Normalised EBITDA surged to NZ$12.6M from NZ$4.2M in FY25, with the company maintaining a solid cash position of NZ$27.1M and no debt. FY27 guidance projects 13-23% constant currency revenue growth to NZ$115-125M, though Normalised EBITDA is expected to moderate to NZ$8-11M due to deliberate investment of ~NZ$9M in commercial expansion and product development. Key points: Revenue of NZ$103.9M exceeded FY26 guidance range of NZ$92-100M, growing 23% YoY with 54% Myriad product growth demonstrating strong operating leverage; Normalised EBITDA surged to NZ$12.6M (+200% YoY), exceeding guidance of NZ$5-8M despite cost inflation, demonstrating significant margin expansion; Strong cash generation with NZ$10.5M operating cash inflow (vs NZ$2.6M outflow in FY25), ending with NZ$27.1M cash, no debt, and net cash flow of NZ$5.1M
Earnings Release - 26 May 2026
Upcoming earnings release expected 26 May 2026 (from Yahoo Finance (confirmed))
Notification of Full Year Results Webinar
Aroa Biosurgery Limited (ASX: ARX) will host a webinar on 26 May 2026 at 9 AM AEST with CEO Brian Ward and CFO James Agnew to discuss the Company's Full Year 2026 Audited Financial Results, which will be released pre-market the same day.
Get real-time alerts for ARX
Receive AI-powered earnings summaries and instant notifications when Aroa Biosurgery Limited releases results.
Register Free